About one-third of patients with major depressive disorder don’t respond adequately to antidepressant medications that are currently available.
In recent years, there has been a lot of interest in the use of intravenous ketamine for the treatment of major depressive disorder that has failed to respond to antidepressant medications. But, large-scale use of intravenous ketamine is impractical.
What is esketamine? It is an enantiomer of ketamine. What this means is that ketamine is a mixture of S-ketamine (esketamine) and R-ketamine (arketamine), molecules that are identical in composition but mirror images of each other. S-ketamine has higher affinity for the NMDA receptor than R-ketamine.
Intranasal esketamine is being developed as a potential treatment for major depressive disorder.
This is the first clinical trial of intranasal esketamine for “treatment-resistant depression.”
It aimed to assess the efficacy, safety, and dose-response of intranasal esketamine in these patients.